secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclo Therapeutics, Inc. (—)
CIK:        0000922247
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001437749-23-035449
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclo Therapeutics completes all-stock merger with Applied Molecular Transport; issues ~5.8M shares
--------------------------------------------------------------------------------

- Merger closed; AMTI stockholders receive 0.1331 CYTH shares per AMTI share.
- Cyclo issued ~5.82M shares to AMTI holders, representing ~18% of combined fully diluted company.
- Combined co continues as Cyclo Therapeutics (CYTH); primary focus on Phase 3 Trappsol Cyclo for NPC1.
- Pro forma cash ~$11.0M; expected operating runway into 2H 2024.
- Shawn Cross, former AMTI CEO, appointed to Cyclo board as independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/922247/000143774923035449/0001437749-23-035449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/922247/000143774923035449/ctdh20231227_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-035449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer